Study sheds new light on aggressive childhood cancer

EU-funded researchers have uncovered some of the complex molecular mechanisms that drive the growth of neuroblastoma, a type of cancer found in very young children. The scientists hope that their findings, published in the journal Cancer Cell, will lead to the development of new therapies to treat this often aggressive and unpredictable disease.

EU support for the study came from the IMPACT (Identification of novel targets for cancer therapy) project, which is financed through the 'Life sciences, genomics and biotechnology for health' Thematic area of the Sixth Framework Programme (FP6).

Neuroblastoma is a cancer of the nervous system that primarily affects children under the age of five years. During normal development, neural crest cells stop dividing and turn into different types of mature nerve cells. However, in neuroblastoma, this does not happen and the cells simply keep dividing, forming a tumour.

The tumour most commonly develops in the abdomen, often in the adrenal glands or the nerve tissue towards the back of the abdomen. However, it can also spread to other parts of the body through the blood and lymphatic system. Symptoms vary depending on where the disease is located and whether it has spread to other parts of the body. Because the symptoms are often vague (including tiredness, fever and loss of appetite) in the early stages of the disease, neuroblastoma is often difficult to diagnose.

Previous work has shown that high levels of a gene called MYCN are often linked to treatment resistance and poor prognosis. MYCN disrupts the control of cell division and differentiation. The researchers analysed 194 other genes that are either dependent on high levels of MYCN activity in the neuroblastoma cells or are targeted directly by genes of the Myc family.

They found that a gene called AURKA is required for the growth of MYCN-amplified tumours, but is not needed by cells lacking amplified MYCN. AURKA is a well-known cancer gene that has already been implicated in the growth of other types of tumour in humans.

The AURKA gene codes for an enzyme called Aurora A that binds to and stabilises N-Myc, and the researchers suggest this in turn contributes to the development of neuroblastoma by interfering with the maturation of developing nerve cells. The researchers also found that Aurora A's ability to stabilise N-Myc is not linked to its enzymatic properties. Therefore, potential drugs designed to block its enzymatic properties may not block its interactions with N-Myc.

"Our results show that stabilisation of N-Myc is a critical oncogenic function of Aurora A in childhood neuroblastoma; the challenge will now be to find ways to interfere with this function in order to find new approaches for the therapy of these tumours," commented Dr Martin Eilers of the University of Würzburg in Germany. "The findings also suggest that the current views about why Aurora A is oncogenic may need to be re-evaluated."

For more information, please visit:
http://www.imt.uni-marburg.de/intact/

Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...